BioCardia Statistics
Total Valuation
BioCardia has a market cap or net worth of $9.87 million. The enterprise value is $9.33 million.
| Market Cap | 9.87M |
| Enterprise Value | 9.33M |
Important Dates
The last earnings date was Friday, May 15, 2026, before market open.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioCardia has 11.37 million shares outstanding. The number of shares has increased by 135.69% in one year.
| Current Share Class | 11.37M |
| Shares Outstanding | 11.37M |
| Shares Change (YoY) | +135.69% |
| Shares Change (QoQ) | +1.27% |
| Owned by Insiders (%) | 19.95% |
| Owned by Institutions (%) | 13.08% |
| Float | 8.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.41
| Current Ratio | 0.41 |
| Quick Ratio | 0.35 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -252.00% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 733.40% |
| Weighted Average Cost of Capital (WACC) | 6.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$370,238 |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.21% in the last 52 weeks. The beta is 0.50, so BioCardia's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -60.21% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 43.56 |
| Average Volume (20 Days) | 8,146,712 |
Short Selling Information
The latest short interest is 329,380, so 2.90% of the outstanding shares have been sold short.
| Short Interest | 329,380 |
| Short Previous Month | 245,775 |
| Short % of Shares Out | 2.90% |
| Short % of Float | 3.76% |
| Short Ratio (days to cover) | 0.96 |
Income Statement
| Revenue | n/a |
| Gross Profit | -4.67M |
| Operating Income | -7.82M |
| Pretax Income | -7.78M |
| Net Income | -7.78M |
| EBITDA | -7.80M |
| EBIT | -7.82M |
| Earnings Per Share (EPS) | -$0.95 |
Balance Sheet
The company has $951,000 in cash and $412,000 in debt, with a net cash position of $539,000 or $0.05 per share.
| Cash & Cash Equivalents | 951,000 |
| Total Debt | 412,000 |
| Net Cash | 539,000 |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | -1.07M |
| Book Value Per Share | -0.10 |
| Working Capital | -1.64M |
Cash Flow
In the last 12 months, operating cash flow was -$7.48 million and capital expenditures -$10,000, giving a free cash flow of -$7.49 million.
| Operating Cash Flow | -7.48M |
| Capital Expenditures | -10,000 |
| Depreciation & Amortization | 15,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.49M |
| FCF Per Share | -$0.66 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioCardia does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -135.69% |
| Shareholder Yield | -135.69% |
| Earnings Yield | -78.80% |
| FCF Yield | -75.88% |
Analyst Forecast
The average price target for BioCardia is $15.50, which is 1,686.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.50 |
| Price Target Difference | 1,686.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 30, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | May 30, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |